· GluCurve is the world’s first continuous glucose monitor (CGM) for diabetic dogs and cats
· GluCurve eliminates need for manual, costly and cumbersome “glucose curves” that are today’s standard of care
· 2017 AVMA Report shows between 28,000-32,000 veterinary practices in U.S.
· 97% of DVM survey respondents indicated they’d use a pet CGM system to diagnose and manage diabetic dogs and cats as soon as available
SINGAPORE, Oct 22 (Bernama-GLOBE NEWSWIRE) — ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, is pleased to release select results from comprehensive market research conducted by the consulting firm SmartPharma, evaluating the current approach to diabetes diagnosis, glucose monitoring and insulin treatment in cats and dogs. The conclusions speak strongly about the market demand for innovation to modernize the arcane standard of care today, which ALRT interprets as highly favorable for introducing the GluCurve™ Pet CGM (continuous glucose monitoring) as a simple, accurate, reliable and pain-free system to treat the approximately 4.5 million diabetic dogs and cats worldwide.
- Independent Review Panel Released Final Report On UNRWA
- Eyeing China, EU parliament to back ban on forced labour
- Tensions flare at US universities over Gaza protests
- Iraq, Türkiye Sign Over 20 Deals To Boost Ties
- ‘Staggering’ number of workers facing climate change-induced health hazards: UN
- Iran Vows “Harsher” Response Should Israel “Make Another Mistake”
- Philippine Terrorist Group Leader, 11 Others Killed In Clash
- S. Korean President Names 5-Term Lawmaker As Chief Of Staff
- Iraqi Fighters Fired Rockets At U.S. Base In Syria: Source
- China Ready To Work With Cambodia To Promote Community With Shared Future: Wang Yi
